PROTAC
HomePROTAC

PROTAC

Catalog No. Product Name Information
S0070 Gefitinib-based PROTAC 3 Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively.
S0072 MS4078 MS4078 is an inhibitor and PROTAC (degrader) of ALK. MS4078 reduces the NPM-ALK protein levels in SU-DHL-1 cells and the EML4-ALK protein levels in NCI-H2228 cells with DC50 of 11 nM and 59 nM, respectively. MS4078 induces ALK protein degradation via cereblon and proteasome dependent mechanism and potently inhibits proliferation of SU-DHL-1 cells with IC50 of 33 nM.
S0137 dBET57 dBET57 is a novel, potent and selective degrader of BRD4BD1 based on the PROTAC technology with DC50/5h of 500 nM. dBET57 is inactive on BRD4BD2.
S8296 dBET1 dBET1 is a CRBN-based BET degrader with an IC50 of 20 nM, showing highly selectivity. Out of 7,429 proteins, only the expression of the oncoproteins MYC and PIM1, as well as BRD2, BRD3 and BRD4 are significantly downregulated by dBET1 treatment.
S8297 ARV-825 ARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
S8532 ARV-771 ARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
S8762 dBET6 dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.
S8785 A1874 A1874 is a much improved nutlin-based, BRD4-degrading PROTAC and is able to degrade its target protein by 98% with nanomolar potency.
S8888 GMB-475 GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
S0603 m-PEG12-amine m-PEG12-amine is a PEG-based PROTAC linker that can be applied into the synthesis of PROTACs. m-PEG12-amine is also a non-cleavable 12-unit PEG ADC linker applied into the synthesis of antibody-drug conjugates (ADCs).
S1127 3-Maleimidopropionic acid 3-Maleimidopropionic acid is an alkyl chain-based PROTAC linker that is applicable to the synthesis of PROTACs.
S1246 NH2-PEG3-C2-NH-Boc NH2-PEG3-C2-Boc (PROTAC Linker 15) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
S1350 Bis-PEG3-acid Bis-PEG3-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
S1661 EdU (5-Ethynyl-2'-deoxyuridine) EdU (5-Ethynyl-2'-deoxyuridine), a thymidine analogue, which can be incorporated into cellular DNA and the subsequent reaction of EdU with a fluorescent azide in a copper-catalyzed [3+2] cycloaddition ("Click" reaction) are developed as a method for detection of DNA synthesis. 5-Ethynyl-2'-deoxyuridine is an alkyl chain-based PROTAC linker that is applicable to the synthesis of PROTACs.
S1664 Di(N-succinimidyl) adipate Di(N-succinimidyl) adipate (DSAP) is an alkyl chain-based PROTAC linker that is applicable to the synthesis of PROTACs.
S1697 Heptaethylene glycol Heptaethylene glycol (HO-PEG7-OH) is a PEG-based PROTAC linker that is applicable to the synthesis of PROTACs.
S1772 Bis-NH2-C1-PEG3 Bis-NH2-C1-PEG3 (PROTAC Linker 24) is a PEG-based PROTAC linker that is applicable to the synthesis of PROTACs.
S1803 5-Boc-amino-pentanoic acid 5-Boc-amino-pentanoic acid (Boc-5-aminovaleric acid, Boc-NH-C4-acid, Boc-5-Ava-OH) is a PROTAC linker that belongs to a Alkyl/ether linker. Boc-NH-C4-acid is applicable to the synthesis of PROTAC1, and specifically degrades EED, EZH2, and SUZ12 in the PRC2 Complex.
S1814 tert-Butyl 11-aminoundecanoate tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker that refers to the PEG composition. tert-Butyl 11-aminoundecanoate is applicable to the synthesis of a series of PROTACs.
S1846 Hydroxy-PEG4-O-Boc Hydroxy-PEG4-O-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
S1872 Amino-PEG1-C2-acid Amino-PEG1-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
S1912 3,6,9-Trioxaundecanedioic Acid 3,6,9-Trioxaundecanedioic acid is a PEG-based PROTAC linker that is applicable to the synthesis of PROTACs.
S0095 VL285 VL285 is a potent VHL ligand that degrades HaloTag7 fusion proteins. Cotreatment with excess VL285, the core VHL ligand from which HaloPROTAC3 is derived, is able to significantly reduce HaloPROTAC3 mediated activity to 50% degradation.
S0097 (S,R,S)-AHPC (MDK7526) (S,R,S)-AHPC (MDK7526, VH032-NH2, VHL ligand 1) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC is potential useful for the targeted degradation of the androgen receptor. (S,R,S)-AHPC can be connected to the ligand for protein such as BCR-ABL1 by a linker to form PROTACs such as GMB-475. GMB-475 induces the degradation of BCR-ABL1 with IC50 of 1.11 μM in Ba/F3 cells.
S0322 BC-1215 BC-1215 is an inhibitor of F-box protein 3 (Fbxo3, a ubiquitin E3 ligase component) with IC50 of 0.9 μg/mL and LC50 of 87 μg/ml for IL-1β release. BC-1215 inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6.
S1015 Thalidomide-OH Thalidomide-OH (Cereblon ligand 2, E3 ligase Ligand 2) is a presumed hydroxylated thalidomide metabolite, with weak antiangiogenic activity (the average inhibition rate of vessel density was 14% in 100 μg), also can be applicable to the recruitment of CRBN protein.
S1016 Lenalidomide-Br Lenalidomide-Br is a brominated analog of lenalidomide, designed for use as a chemical tool in PROTAC research. It serves as a cereblon (CRBN)-recruiting ligand, enabling targeted protein degradation through the CRL4CRBN E3 ubiquitin ligase complex.
S1029 Lenalidomide Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
S1062 (S,R,S)-AHPC hydrochloride (S,R,S)-AHPC hydrochloride (VH032-NH2, VHL ligand 1) is the VH032-based VHL ligand that is applicable to the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein by a linker to form PROTACs.
S1193 Thalidomide Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1.
S1567 Pomalidomide Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
S6794 Thalidomide-O-COOH (Cereblon ligand 3) Thalidomide-O-COOH (Cereblon ligand 3, E3 ligase Ligand 3), a Thalidomide-based Cereblon (CRBN) ligand, is used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs (Proteolysis Targeting Chimera).
S8760 Iberdomide (CC220) Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
S1526 Quizartinib (AC220) Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Quizartinib (AC220) induces apoptosis of tumor cells. Phase 3.
S2680 Ibrutinib Ibrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
S6545 BI-4464 BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM.
S7110 (+)-JQ1 (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy. (+)-JQ1 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.